No headlines found.
No press releases found.
No news found.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
Xbiotech trades on the NASDAQ stock market under the symbol XBIT.
As of May 13, 2024, XBIT stock price climbed to $8.80 with 14,844 million shares trading.
XBIT has a beta of 1.35, meaning it tends to be more sensitive to market movements. XBIT has a correlation of 0.05 to the broad based SPY ETF.
XBIT has a market cap of $267.87 million. This is considered a Small Cap stock.
In the last 3 years, XBIT stock traded as high as $18.46 and as low as $3.00.
The top ETF exchange traded funds that XBIT belongs to (by Net Assets): VTI, VXF, BSVO, IWC, AVUV.
XBIT has outperformed the market in the last year with a price return of +167.5% while the SPY ETF gained +27.9%. XBIT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +49.7% and +11.8%, respectively, while the SPY returned +4.3% and +2.5%, respectively.
XBIT support price is $7.83 and resistance is $8.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XBIT stock will trade within this expected range on the day.